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Background: The soluble factor ps20 encoded by the human
WFDC1 gene on Chromosome 16, is an ancient whey acidic protein
(WAP) family member, characterized by highly evolutionarily con-
served domain comprising eight cysteines that make 4 disulphide
bonds. WAPs are soluble innate immune mediators implicated
in homeostatic control of inﬂammation and broad anti-infective
activities. Previous studies in our laboratory highlighted a novel
function of ps20. We demonstrated ps20 expression in CD4-T cells,
which rendered these cells highly susceptible to HIV infection
through up-regulation of ICAM-1. Consistentwith this observation,
we showed that plasma ps20 levels positively correlated to CD4-
T cell count. We also demonstrated that ps20 levels at the CD4-T
cell level showed a strikingly inverse relationship with IFNg and
silencing of ps20 in CD4-T cell clones led to upregulation of IFNg.
This studywas designed to further examine the role of ps20 in IFNg
regulation in a chronic infection, such as TB, where IFNg levels are
known to be impaired.
Methods & Materials: (i) An in-house ps20-speciﬁc sandwich
ELISA was calibrated and used to conﬁrm ps20 levels in plasma
of 30 treatment naïve active TB, 15 TB treated (12 months post
treatment), 12 IGRA+ and 10 IGRA- subjects.
(ii) To further test if raised plasma ps20 in active TB correlated
with reduced IFNg expression, we measured the ps20 and IFNg
mRNA and protein levels in PBMC cultured activatedwith PHA/IL-2
in time-course assays.
(iii) Rapamycin, a known regulator of the mTOR pathway is
well established inhibitor of IFNg expression. We therefore used
this regulator to further determine if suppression of IFNg leads to
induction of ps20.
Results: (i) The ELISA data showed active TB subjects had a sig-
niﬁcantly higher (p =0.0356) plasma ps20 compared to IGRA+ and
IGRA- subjects.
(ii) PHA/IL-2 immunomodulation data conﬁrm active TB sub-
jects to have lower IFNg than IGRA+ and IGRA- subjects with
concomitantly higher ps20 expression.
(iii) Rapamycin Inhibition assay conﬁrms IFNg expression to be
signiﬁcantly reduced in thepresenceof Rapamycinwith a concomi-
tant marginal but consistent induction of ps20.
Conclusion: These studies highlight ps20 may be a novel regu-
lator of IFNg and provide novel insights on the possible role of ps20
in TB pathogenesis
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Abstract: The human body habitats are home to an array of
micro-organisms, and within these microbial ecosystems there is
an exchange of genetic material, including antibiotic resistance
genes. Recent metagenomic studies revealed that the human gut
microbiota is a reservoir of antibiotic resistant genes (the gut resis-
tome).However, little is knownabout thediversity andabundances
of antibiotic resistance genes in other body habitats and how that
compares to the gut resistome. By leveraging the most compre-
hensive human microbiome dataset of healthy adults generated by
the human microbiome project, we characterize the human micro-
biome resistome from four body habitats including gut (stool), oral,
anterior nares and vagina. The human resistomewas proﬁled using
ametagenomic shotgun sequencing alignment-based approach. By
determining the resistome size per individual we found resistance
genes distribute distinctly by body sites with certain body habitats
being abetter reservoirs thenothers. Furthermore,while resistance
classes were incoming among body habitats (e.g. tetracyclin), the
speciﬁc resistance genes per class were different (e.g. tetM in oral
vs tetQ in gut). The proﬁles of resistance genes (in the body sites
with universally present resistance genes) are more similar for the
same subjects over time than between subjects at the same time of
sampling. Finally, association analysis with sex, age and geography
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showedcertain signiﬁcant correlation forhabitat speciﬁc resistance
genes. These ﬁndings illustrate that the healthy human microbiota
in general, beyond the gut microbiota, is a reservoir for antibiotic
resistance genes. This reservoir may serve as a mobile resistance
gene pool that facilitates the transmission of antibiotic resistance
genes.
http://dx.doi.org/10.1016/j.ijid.2016.02.118
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Abstract: Through analytical advances, the complexity of the
human microbiome has recently become apparent. The emerging
data have shed light on the microorganisms living in intimate rela-
tionship with each cell in the body, and on how much of a person’s
daily function and health depends on this symbiosis. Fecal micro-
biota transplantation (FMT), also called bacteriotherapy, refers to
the infusion of a fecal suspension from one individual into the
gastrointestinal tract of another person, most often performed to
cure diseases caused by microbial dysbiosis. FMT is by no means a
new therapeutic modality, and was described as early as the ﬁfth
century. Nevertheless, until recently, only few peer-reviewed case
reports could be found in the medical literature. In the past 3 years,
stool has emergedas abiologically active, complexmixtureof living
organisms with great therapeutic potential for a number of dis-
eases, most notably recurrent Clostridium difﬁcile infection (CDI).
Many case series and a number of clinical trials have repeatedly
shown high cure rates, of up to 93%, in patients with recurrent
CDI, compared with 30-40% cure obtained with standard antimi-
crobial treatment. FMT can be delivered via enema, colonoscopy,
nasoduodenal tube, nasogastric tube and orally, as encapsulated
FMT. An overview will be given about the current knowledge with
regard to efﬁcacy and safety of different delivery methods, focus-
ing on oral therapy as themost convenient and cost-effective route.
The development of the FMT capsule will be described as will our
experience providing FMT to over 200 patients as part of clini-
cal trials or routine care, including long-term follow up data. Few
FMT-related adverse events have been reported to date, and most
were related to the delivery mechanism. The potential use of FMT
for other indications will be brieﬂy explored, including inﬂamma-
tory bowel diseases, functional bowel disorders, de-colonization of
resistantpathogens and, throughmodiﬁcationof thegut-brain axis,
neuropsychiatric disorders.
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Abstract: Bacteria populated the earth two billion years prior to
emergence of eukaryotic life. Now, some 400-500 species are esti-
mated to inhabit the humanmucosal surfaces, bulk of which reside
in the intestinal tract. Traditionally, a newborn gut was considered
sterile, but new evidence indicate presence of bacteria in the fetus
and meconium. Mode of delivery, feeding type, the environment,
and caregivers provide the initial bacterial exposure to the new-
born to help develop a healthy colonization pattern. There is ample
evidence in favor of simple problems such as feeding intolerance
to very severe diseases such as necrotizing enterocolitis resulting
in part due to disruption of normal microbiota. However, there is
paucity of data on a “true” healthy microbial pattern in neonates.
Similarly, most of the work done on neonatal microbiome is from
thewest and a comparative comparison ofmicrobiota has not been
done in babies from different parts of the world. Apart from act-
ing against pathogens and maintaining homeostasis in infectious,
inﬂammatory, and autoimmune diseases, the intestinal microbiota
has now been a focus of attention in their role in vaccine response.
Maturation of mucosal immune system as a result of coloniza-
tion by bacteria has been known for some time, and new research
in humans and animals provides clear evidence of a bacterial role
in the development of both innate and adaptive immune response
in the mammalian host. The type, number, and timing of exposure
of mucosal and dendritic cells to bacteria and bacterial products
and induction of speciﬁc T helper and T- regulatory components
of the immune system have been examined with some details in
different disease models. We will discuss these and other factors
currently known to play a role and their mechanism in modulating
the infant immune response. Recent results from an Indian pro-
biotic trial in neonatal sepsis using live bacteria in the ﬁrst week
of life will be presented in light of its mucosal effects in blockage
of bacterial translocation and possible extra-intestinal impacts via
modulation of innate immunity.
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